← All trials
NCT07014826
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Jun 11, 2025
- Last posted
- Aug 5, 2025
- Enrollment
- 378
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.